Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Inflammatory Bowel Diseases

Free Subscription 21.04.2025 2 Aliment Pharmacol Ther 1 Am J Gastroenterol 4 Clin Gastroenterol Hepatol 1 Clin Res Hepatol Gastroenterol 5 Dig Dis Sci 2 Gastroenterology 6 Inflamm Bowel Dis 4 J Crohns Colitis 1 J Gastroenterol 2 Lancet Gastroenterol Hepatol 2 Mediators Inflamm 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. RICHARD N, Fumery M
   Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply.
   Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70149.
   PubMed        
   
   
2. RAMOS-BELINCHON C, Plevris N
   Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease?
   Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70113.
   PubMed        
   
   

   
   Am J Gastroenterol

3. YANG JC, Janssen EM, Wallace MJ, Sheahan A, et al
   Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease.
   Am J Gastroenterol. 2025 Mar 6. doi: 10.14309/ajg.0000000000003397.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

4. LE BERRE C, Jairath V, Panaccione R, Bourreille A, et al
   Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review.
   Clin Gastroenterol Hepatol. 2025 Apr 10:S1542-3565(25)00278.
   PubMed         Abstract available
   
   
5. HUANG Z, Diao N, Guo Q, Li M, et al
   Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naive Crohn's Disease.
   Clin Gastroenterol Hepatol. 2025 Apr 14:S1542-3565(25)00285.
   PubMed         Abstract available
   
   
6. LARSON C, Berinstein JA, Tedesco N, Seidelin JB, et al
   Postoperative Outcomes in Tofacitinib-treated Patients with Acute Severe Ulcerative Colitis Undergoing Colectomy.
   Clin Gastroenterol Hepatol. 2025 Apr 14:S1542-3565(25)00287.
   PubMed         Abstract available
   
   
7. SINGH A, Bhardwaj A, Sharma R, Jain D, et al
   Effectiveness and Safety of Tofacitinib in Biologic-Naive Elderly Patients with Ulcerative Colitis.
   Clin Gastroenterol Hepatol. 2025 Apr 15:S1542-3565(25)00292.
   PubMed        
   
   

   
   Clin Res Hepatol Gastroenterol

8. CHEN M, Gao X, Cao Q, Rossiter G, et al
   Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease.
   Clin Res Hepatol Gastroenterol. 2025 Apr 12:102591.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

9. SETHI S, Puri R, Jain HP, Ashwin DK, et al
   A Rare Cause of Terminal Ileal Ulcer: Beyond Tuberculosis and Crohn's Disease.
   Dig Dis Sci. 2025 Apr 18. doi: 10.1007/s10620-025-09023.
   PubMed        
   
   
10. VAN DE POL N, Visser EH, van Noord D, van der Woude CJ, et al
    Evaluation of an Exercise Program in Patients with Inflammatory Bowel Disease: A Pilot Study.
    Dig Dis Sci. 2025 Apr 17. doi: 10.1007/s10620-025-09030.
    PubMed         Abstract available
    
    
11. OOMKENS D, Mujagic Z, de Vries A, van der Meulen-de Jong A, et al
    Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study.
    Dig Dis Sci. 2025 Apr 16. doi: 10.1007/s10620-025-09052.
    PubMed         Abstract available
    
    
12. SAWAF B, Abbarh S, Alsoud D
    Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance?
    Dig Dis Sci. 2025 Apr 16. doi: 10.1007/s10620-025-09047.
    PubMed        
    
    
13. VLADIMIROVA N, Zhao M, Ornbjerg LM, Moller JM, et al
    Musculoskeletal Symptoms and Clinical Findings in Bio-naive Patients with Inflammatory Bowel Disease Prior to Biological Treatment Initiation: A Prospective Cohort Study.
    Dig Dis Sci. 2025 Apr 15. doi: 10.1007/s10620-025-09016.
    PubMed         Abstract available
    
    

    
    Gastroenterology

14. WU X, Li Y, Li P, Lu G, et al
    Structural variations in ulcerative colitis-associated E. coli reduce fructose utilization and aggravate inflammation under high fructose diet.
    Gastroenterology. 2025 Apr 16:S0016-5085(25)00635.
    PubMed         Abstract available
    
    
15. ALLOCCA M, Falloon K, Danese S, Rieder F, et al
    Monitoring the calm before the storm - A video capsule endoscopy guided proactive treat-to-target approach in Crohn's disease.
    Gastroenterology. 2025 Apr 10:S0016-5085(25)00631.
    PubMed        
    
    

    
    Inflamm Bowel Dis

16. REGUEIRO MD, Bewtra M, Dubinsky MC, Branquinho D, et al
    Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States.
    Inflamm Bowel Dis. 2025 Apr 12:izaf067. doi: 10.1093.
    PubMed         Abstract available
    
    
17. GROSSBERG LB, Mishra K, Rabinowitz LG, Mecsas-Faxon B, et al
    A Multicenter Study to Assess Avoidant/Restrictive Food Intake Disorder in Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Apr 13:izaf016. doi: 10.1093.
    PubMed         Abstract available
    
    
18. BULDUKOGLU OC, Ocal S, Cekin AH
    Alterations in Pain Perception in Inflammatory Bowel Disease Patients with Psychiatric Comorbidity.
    Inflamm Bowel Dis. 2025 Apr 13:izaf074. doi: 10.1093.
    PubMed        
    
    
19. PATEL PV, Goyal A
    Editorial: Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Apr 16:izaf049. doi: 10.1093.
    PubMed        
    
    
20. HACKER KS, Friedlander A
    Inclusive Inflammatory Bowel Disease Care for Sexual and Gender Minorities: An Urgent Need in Uncertain Times.
    Inflamm Bowel Dis. 2025 Apr 16:izaf059. doi: 10.1093.
    PubMed        
    
    
21. 
    Correction to: Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations.
    Inflamm Bowel Dis. 2025 Apr 17:izaf075. doi: 10.1093.
    PubMed        
    
    

    
    J Crohns Colitis

22. COLOMBEL JF, Sandborn WJ, Schreiber S, Danese S, et al
    Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY).
    J Crohns Colitis. 2025 Apr 17:jjaf060. doi: 10.1093.
    PubMed         Abstract available
    
    
23. VERSTOCKT B, Alsoud D, van Oostrom J, Verstockt S, et al
    Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.
    J Crohns Colitis. 2025 Apr 17:jjaf063. doi: 10.1093.
    PubMed         Abstract available
    
    
24. WONG ECL, Dulai PS, Marshall JK, Laroux S, et al
    Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial.
    J Crohns Colitis. 2025;19:jjae171.
    PubMed         Abstract available
    
    
25. RASMUSSEN J, Norgard BM, Boggild H, Qvist N, et al
    Labor Market Participation and Income in Patients With Inflammatory Bowel Disease Onset Before Young Adulthood-The Role of Disease Severity and Mental Health.
    J Crohns Colitis. 2025;19:jjae165.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

26. UENO N, Sakatani A, Ando K, Saito S, et al
    Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.
    J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02248.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

27. UKASHI O, Ben-Horin S
    Appendicectomy: a novel treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00065.
    PubMed        
    
    
28. 
    Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00026.
    PubMed         Abstract available
    
    

    
    Mediators Inflamm

29. LUO C, Tian B, Zhou Y, Luo J, et al
    Deciphering the Interplay Among Inflammatory Bowel Disease, Gut Microbiota, and Inflammatory Biomarkers in the Risk of Colorectal Cancer.
    Mediators Inflamm. 2025;2025:4967641.
    PubMed         Abstract available
    
    
30. YUAN T, Xing J, Liu P
    Identification of Crohn's Disease-Related Biomarkers and Pan-Cancer Analysis Based on Machine Learning.
    Mediators Inflamm. 2025;2025:6631637.
    PubMed         Abstract available
    
    

    
    PLoS One

31. LEE J, Kim B
    Zero inflated high dimensional compositional data with DeepInsight.
    PLoS One. 2025;20:e0320832.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.